ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 8, 2014, Pages 2195-2201

  Manosuthi, Weerawat ^a   Sukasem, Chonlaphat ^b   Thongyen, Supeda ^a   Nilkamhang, Samruay ^a   Sungkanuparph, Somnuek ^b  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

HIV; Kidney; Thailand; Transporter

Indexed keywords

CREATININE; EFAVIRENZ; LAMIVUDINE; TENOFOVIR; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; PHOSPHONIC ACID DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; GENETIC VARIABILITY; GENOTYPE; GLOMERULUS FILTRATION RATE; GLUCOSURIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY CLEARANCE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PROSPECTIVE STUDY; PROTEINURIA; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; ANALOGS AND DERIVATIVES; BLOOD; DRUG COMBINATION; DRUG EFFECTS; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; KIDNEY; METABOLISM; PHYSIOLOGY;

ADENINE; ADULT; ANTI-HIV AGENTS; BENZOXAZINES; CREATININE; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HIV-1; HUMANS; KIDNEY; LAMIVUDINE; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANOPHOSPHONATES; POLYMORPHISM, SINGLE NUCLEOTIDE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84904577735     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku129     Document Type: Article

References (25)

1. Kalyesubula R, Perazella MA. Nephrotoxicity of HAART. AIDS Res Treat 2011; 2011: 562790.
2. Brennan A, Evans D, Maskew M et al. Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir. AIDS 2011; 25: 1603-9.
3. Thompson MA, Aberg JA, Hoy JF et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308: 387-402.
4. Williams I, Churchill D, Anderson J et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med 2012; 13 Suppl 2: 1-85.
5. Gallant JE, Deresinski S. Tenofovir disoproxil fumarate. Clin Infect Dis 2003; 37: 944-50.
6. Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat 2011; 2011: 354908.
7. Hoffmeyer S, Burk O, von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-8.
8. Ray AS, Cihlar T, Robinson KL et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 2006; 50: 3297-304.
9. Van Rompay KK, Durand-Gasselin L, Brignolo LL et al. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother 2008; 52: 3144-60.
10. Rodriguez-Novoa S, Labarga P, D'Avolio A et al. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS 2010; 24: 1064-6.
11. Herlitz LC, Mohan S, Stokes MB et al. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int 2010; 78: 1171-7.
12. Wever K, van Agtmael MA, Carr A. Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. J Acquir Immune Defic Syndr 2010; 55: 78-81.
13. Rodriguez-Novoa S, Labarga P, Soriano V. Pharmacogenetics of tenofovir treatment. Pharmacogenomics 2009; 10: 1675-85.
14. Imaoka T, Kusuhara H, Adachi M et al. Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol 2007; 71: 619-27.
15. Rodriguez-Novoa S, Labarga P, Soriano V et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis 2009; 48: e108-16.
16. Izzedine H, Hulot JS, Villard E et al. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis 2006; 194: 1481-91.
17. Nishijima T, Komatsu H, Higasa K et al. Single nucleotide polymorphisms in ABCC2 associate with tenofovir-induced kidney tubular dysfunction in Japanese patients with HIV-1 infection: a pharmacogenetic study. Clin Infect Dis 2012; 55: 1558-67.
18. Goicoechea M, Liu S, Best B et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 2008; 197: 102-8.
19. Bagnis CI, Karie S, Deray G et al. Hypophosphataemia: an easy strategy for diagnosis and treatment in HIV patients. Antivir Ther 2009; 14: 481-8.
20. Pushpakom SP, Liptrott NJ, Rodriguez-Novoa S et al. Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. J Infect Dis 2011; 204: 145-53.
21. Gagnieu MC, Barkil ME, Livrozet JM et al. Population pharmacokinetics of tenofovir in AIDS patients. J Clin Pharmacol 2008; 48: 1282-8.
22. Gallant JE, Staszewski S, Pozniak AL et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292: 191-201.
23. ManosuthiW, PrasithsirikulW, Tantanathip P et al. Renal impairment in HIV-1 infected patients receiving antiretroviral regimens including tenofovir in a resource-limited setting. Southeast Asian J Trop Med Public Health 2011; 42: 643-50.
24. Manosuthi W, Mankatitham W, Lueangniyomkul A et al. Renal impairment after switching from stavudine/lamivudine to tenofovir/ lamivudine in NNRTI-based antiretroviral regimens. AIDS Res Ther 2010; 7: 37.
25. Cooper RD, Wiebe N, Smith N et al. Systematic review and metaanalysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010; 51: 496-505.